Asia-Pacific Continuous Bioprocessing Market to be Worth $181.1 Million by 2030

Asia-Pacific Continuous Bioprocessing Market by Product (Filtration, Chromatography, Centrifuges, Consumables), Application (Commercial {Vaccines, Monoclonal Antibodies}, R&D), End User (Pharmaceuticals, Biotechnology, CROs) – Forecast to 2030

The Asia-Pacific Continuous Bioprocessing Market is expected to grow at a CAGR of 28.9% from 2023 to 2030 to reach $181.1 million by 2030. Continuous manufacturing is an emerging trend spanning various industries. From automotive to paper, businesses are embracing continuous manufacturing to enhance efficiency and bolster profits. The shift from batch to continuous manufacturing is gaining traction in the biopharmaceuticals sector due to the surge in demand for intricate therapies and heightened market competition. Continuous bioprocessing is increasingly being adopted due to its agility, flexibility, efficiency, and robustness. This approach streamlines processes by minimizing steps, utilizing compact facilities and equipment, and enhancing product quality to facilitate real-time release.

The growth of the continuous bioprocessing market in Asia-Pacific is attributed to the gradual adoption of continuous manufacturing, rising manufacturing and research-related outsourcing of biopharmaceuticals, expansions in CDMOs, and initiatives supporting the adoption of biopharmaceuticals. Furthermore, the shift towards bioprocessing 4.0 and the rising adoption of personalized medicines are expected to provide significant market growth opportunities.

However, the limitations of continuous bioprocessing may restrain the growth of this market. Additionally, manufacturers’ hesitation to shift from batch manufacturing to continuous manufacturing poses challenges to the market players.